| AiRuiKa (camrelizumab) / HLB Bio Group |
| Completed | 2 | 43 | RoW | Apatinib, SHR-1210 | Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd. | Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity | 10/19 | 01/20 | | |
NCT04126993: Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma |
|
|
| Unknown status | 2 | 80 | RoW | Camrelizumab,, Apatinib | Tianjin Medical University Cancer Institute and Hospital | Sarcoma | 12/19 | 12/20 | | |
NCT04294511: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma |
|
|
| Recruiting | 2 | 75 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Osteosarcoma | 03/21 | 09/23 | | |
ChiCTR1900027356: A single-center, randomized, controlled phase II clinical study of carillizumab combined with preoperative radiotherapy for resectable undifferentiated pleomorphic sarcoma |
|
|
| Recruiting | 2 | 24 | | Camrelizumab combined with radiotherapy ;radiotherapy | Affiliated Tumor Hospital of Zhengzhou University; Affiliated Tumor Hospital of Zhengzhou University, Jiangsu hengrui pharmaceutical co. LTD | Undifferentiated pleomorphic sarcoma | | | | |
NCT03711279: A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma |
|
|
| Terminated | 2 | 99 | RoW | SHR-1210 plus Apatinib, PD-1 antibody + Anti-angiogenesis, ADM plus IFO or IFO alone, chemotherapy | Jiangsu HengRui Medicine Co., Ltd. | Sarcoma | 06/21 | 06/21 | | |
NCT04606108: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 62 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Soft Tissue Sarcoma | 10/21 | 03/24 | | |
NCT04447274: A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS |
|
|
| Unknown status | 2 | 20 | NA | Camrelizumab and Apatinib | Chinese Academy of Medical Sciences | Sarcoma | 12/21 | 12/21 | | |
NCT04239443: Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer |
|
|
| Unknown status | 2 | 120 | RoW | PD-1 inhibitor, Camrelizumab, Apatinib | Hunan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd. | Advanced Non Small Cell Lung Cancer, Uterine Cancer, Soft Tissue Sarcoma | 03/22 | 03/22 | | |
ChiCTR2000031478: A single arm, investigative, phase II study of anti-PD-1 antibody SHR1210 in advanced pulmonary sarcomatoid carcinoma who failed to first line chemotherapy |
|
|
| Not yet recruiting | 2 | 38 | | PD-1 antibody SHR1210, 200mg, intravenously, per 3 weeks | Shanghai Pulmonary Hospital; Level of the institution：, Shanghai Pulmonary Hospital | Lung cancer | | | | |
MAPAC, NCT04351308: Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma |
|
|
| Recruiting | 2 | 60 | RoW | MAPI chemotherapy, Apatinib Mesylate, Camrelizumab | Peking University People's Hospital, Chinese Sarcoma Study Group | Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug | 09/22 | 12/22 | | |
NCT04910126: Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 84 | RoW | Camrelizumab, C, Adriamycin, A | Wuhan Union Hospital, China | Soft Tissue Sarcoma, Neoplasms, Connective and Soft Tissue, Sarcoma Metastatic, Sarcoma,Soft Tissue | 01/23 | 11/23 | | |
NCT05265793: Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma |
|
|
| Recruiting | 2 | 45 | RoW | Camrelizumab Combined With Apatinib, PD-1 immunotherapy and VEGFR-TKIs | Fudan University | PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma, Carcinosarcoma | 03/23 | 06/23 | | |
ChiCTR2000032649: A multicenter, open, single-arm, phase II study to evaluate the efficacy and safety of camrelizumab alone or in combination with Apatinib mesylate in patients with PD-L1-positive advanced lung sarcomatoid carcinoma |
|
|
| Not yet recruiting | 2 | 30 | | camrelizumab alone or in combination with Apatinib mesylate | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd | lung sarcomatoid carcinoma | | | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/23 | 06/24 | | |
|
NCT05189483: Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. |
|
|
| Recruiting | 2 | 40 | RoW | Albumin-Bound Paclitaxel, Camrelizumab | Henan Cancer Hospital | Soft Tissue Sarcoma | 07/24 | 07/24 | | |
ChiCTR2100049157: Doxorubicin (A) Plus Camrelizumab (C) Versus Doxorubicin Alone for the First-Line Treatment (T) of Select Type of Adcanced Soft Tissue Sarcoma (ACTS): A Randomised Controlled Multi Centers Trial |
|
|
| Not yet recruiting | 2 | 124 | | Camrelizumab Plus Doxorubicin ;Doxorubicin | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiangsu Hengrui Pharma | Soft Tissue Sarcoma | | | | |
PRIMA, NCT06074692: PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma |
|
|
| Recruiting | 2 | 86 | RoW | Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) | Ruijin Hospital | Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone | 08/26 | 12/26 | | |
NCT04044378: Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma |
|
|
| Withdrawn | 1/2 | 0 | RoW | Famitinib, Ifosfamide, Camrelizumab, camralizumab | Peking University People's Hospital, Peking University Shougang Hospital, Jiangsu HengRui Medicine Co., Ltd. | Effect of Drugs, Progression, Pediatric Cancer | 09/21 | 09/22 | | |
NCT05699811: IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 40 | RoW | MSC-IFNα, Nab paclitaxel, Abraxane, Cyclophosphamide, Anti-PD-1 monoclonal antibody, Toripalimab Injection, Sintilimab Injection, Camrelizumab Injection, Tislelizumab Injection | Chinese PLA General Hospital, Wuxi Sinotide New Drug Discovery Institutes | Locally Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
